IRTC - NASDAQ
iRhythm Technologies, Inc.
$104.56
+1.5%iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotiRhythm Technologies, Inc. Management Team
Mr. Patrick Michael Murphy J.D.
Chief Business & Legal Officer
Compensation
$834,273
Mr. Chad M. Patterson
Chief Commercial Officer
Compensation
$938,822
Mr. Chad M. Patterson
Chief Commercial and Product Officer
Compensation
$938,822
Mr. Daniel G. Wilson
Chief Financial Officer & Principal Financial Officer
Compensation
$749,809
Mr. Daniel G. Wilson
Chief Financial Officer, Principal Financial Officer, EVice President of Corporate Development & Investor Relations
Compensation
$749,809
Dr. Minang P. Turakhia M.D., M.S.
Chief Medical & Scientific Officer and Executive Vice President of Advanced Technologies
Compensation
$829,714
Dr. Minang P. Turakhia M.D., M.S.
Chief Medical & Scientific Officer and Executive Vice President of Product Innovation
Compensation
$829,714
Ms. Stephanie Zhadkevich
Director of Investor Relations
Ms. Sumi Shrishrimal
Executive Vice President & Chief Risk Officer
Mr. Brian Lawrence
Executive Vice President & Chief Technology Officer
Mr. Mervin Smith
Executive Vice President of Business Operations
Mr. Sean Clinton Freeman
Executive Vice President of Strategy & Corporate Development
iRhythm Technologies, Inc. Insider Positioning
During the last 12 months, insiders have purchased $57K and sold $18.57M worth of IRTC shares, resulting in $18.51M of net selling activity.
3 Months
5.3K
56.89K
3.6K
417.96K
-361K
-$361K
3-6 Months
0
0.00
74.2K
10.06M
-10.1M
-$10.06M
6-9 Months
0
0.00
24.9K
4.76M
-4.8M
-$4.76M
9-12 Months
0
0.00
20.6K
3.34M
-3.3M
-$3.34M
Top Buyers
Talwalkar Abhijit Y
Director
$57K
Top Sellers
Blackford Quentin S.
Director, Officer: President And Ceo
$6.08M
Wilson Daniel G.
Officer: Chief Financial Officer
$3.81M
Patterson Chad
Officer: Chief Comm & Product Officer
$2.31M
Murphy Patrick Michael
Officer: Cbo And Clo
$1.51M
Turakhia Minang
Officer: Chief Med/Sci Ofcr Evp Advtech
$1.45M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $18.51M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
IRTC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 17, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 16, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 11, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 12, 2023 | April 12, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | April 14, 2022 | 2022 | |
DEF 14A DEF 14A 2020 N/A | April 30, 2021 | December 31, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2020 | December 31, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | April 25, 2019 | May 22, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 10, 2018 | May 23, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 27, 2017 | June 14, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.